485 related articles for article (PubMed ID: 11336940)
1. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension.
Aung T; Chew PT; Yip CC; Chan YH; See JL; Khng CG; Hoh ST; Ng LH; Lee HM
Am J Ophthalmol; 2001 May; 131(5):636-42. PubMed ID: 11336940
[TBL] [Abstract][Full Text] [Related]
2. Additive effect of unoprostone and latanoprost in patients with elevated intraocular pressure.
Aung T; Chew PT; Oen FT; Chan YH; Thean LH; Yip L; Lim BA; Soh J; Seah SK
Br J Ophthalmol; 2002 Jan; 86(1):75-9. PubMed ID: 11801508
[TBL] [Abstract][Full Text] [Related]
3. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension.
Susanna R; Giampani J; Borges AS; Vessani RM; Jordao ML
Ophthalmology; 2001 Feb; 108(2):259-63. PubMed ID: 11158796
[TBL] [Abstract][Full Text] [Related]
4. Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure.
Jampel HD; Bacharach J; Sheu WP; Wohl LG; Solish AM; Christie W;
Am J Ophthalmol; 2002 Dec; 134(6):863-71. PubMed ID: 12470755
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of latanoprost (Xalatan) and unoprostone (Rescula) in patients with open-angle glaucoma and suspected glaucoma.
Sponsel WE; Paris G; Trigo Y; Pena M
Am J Ophthalmol; 2002 Oct; 134(4):552-9. PubMed ID: 12383812
[TBL] [Abstract][Full Text] [Related]
6. Additive efficacy of unoprostone isopropyl 0.12% (rescula) to latanoprost 0.005%.
Stewart WC; Sharpe ED; Stewart JA; Holmes KT; Latham KE
Am J Ophthalmol; 2001 Mar; 131(3):339-44. PubMed ID: 11239866
[TBL] [Abstract][Full Text] [Related]
7. A comparative clinical study of latanoprost and isopropyl unoprostone in Japanese patients with primary open-angle glaucoma and ocular hypertension.
Tsukamoto H; Mishima HK; Kitazawa Y; Araie M; Abe H; Negi A;
J Glaucoma; 2002 Dec; 11(6):497-501. PubMed ID: 12483094
[TBL] [Abstract][Full Text] [Related]
8. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
[TBL] [Abstract][Full Text] [Related]
9. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
Netland PA; Landry T; Sullivan EK; Andrew R; Silver L; Weiner A; Mallick S; Dickerson J; Bergamini MV; Robertson SM; Davis AA;
Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
[TBL] [Abstract][Full Text] [Related]
10. Effects of latanoprost and unoprostone when used alone or in combination for open-angle glaucoma.
Saito M; Takano R; Shirato S
Am J Ophthalmol; 2001 Oct; 132(4):485-9. PubMed ID: 11589867
[TBL] [Abstract][Full Text] [Related]
11. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma.
Noecker RS; Dirks MS; Choplin NT; Bernstein P; Batoosingh AL; Whitcup SM;
Am J Ophthalmol; 2003 Jan; 135(1):55-63. PubMed ID: 12504698
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension.
Stewart WC; Day DG; Stewart JA; Schuhr J; Latham KE
Am J Ophthalmol; 2001 May; 131(5):631-5. PubMed ID: 11336939
[TBL] [Abstract][Full Text] [Related]
13. A comparison of intraocular pressure-lowering effect of prostaglandin F2 -alpha analogues, latanoprost, and unoprostone isopropyl.
Kobayashi H; Kobayashi K; Okinami S
J Glaucoma; 2001 Dec; 10(6):487-92. PubMed ID: 11740220
[TBL] [Abstract][Full Text] [Related]
14. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study.
Kampik A; Arias-Puente A; O'Brart DP; Vuori ML;
J Glaucoma; 2002 Apr; 11(2):90-6. PubMed ID: 11912355
[TBL] [Abstract][Full Text] [Related]
15. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data.
Nordmann JP; Mertz B; Yannoulis NC; Schwenninger C; Kapik B; Shams N;
Am J Ophthalmol; 2002 Jan; 133(1):1-10. PubMed ID: 11755834
[TBL] [Abstract][Full Text] [Related]
16. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study.
Higginbotham EJ; Olander KW; Kim EE; Grunden JW; Kwok KK; Tressler CS;
Arch Ophthalmol; 2010 Feb; 128(2):165-72. PubMed ID: 20142538
[TBL] [Abstract][Full Text] [Related]
17. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
18. Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States.
Camras CB; Sheu WP;
J Glaucoma; 2005 Apr; 14(2):161-7. PubMed ID: 15741820
[TBL] [Abstract][Full Text] [Related]
19. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
[TBL] [Abstract][Full Text] [Related]
20. Intraocular pressure fluctuations in response to the water-drinking provocative test in patients using latanoprost versus unoprostone.
Susanna R; Medeiros FA; Vessani RM; Giampani J; Borges AS; Jordão ML
J Ocul Pharmacol Ther; 2004 Oct; 20(5):401-10. PubMed ID: 15650515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
